Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company, has appointed Professor David Jones of Newcastle University to its Scientific Advisory Board (SAB). Prof. Jones is renowned for his work in autoimmune liver disease, leading the UK-PBC research consortium and developing stratified therapeutics.

Prof. Jones also serves as Honorary Consultant Hepatologist with the Newcastle upon Tyne Hospitals NHS Foundation Trust. He holds the position of NIHR Dean for Faculty Trainees and is an NIHR Senior Investigator. His expertise in hepatic pathologies and patient quality of life will be valuable as Tharimmune advances its lead drug candidate TH104.

The SAB also includes experts like Andreas Kremer from University Hospital Zurich, Alan Bonder from Harvard University, John Lambert, and Vaughn Smider. Tharimmune recently reported positive Phase 1 results for TH104 and anticipates starting a Phase 2 trial in the second half of 2024.